Metagenomi Therapeutics, Inc. Deferred Revenue Recognized
Metagenomi Therapeutics, Inc. (MGX) had Deferred Revenue Recognized of $2.30 million as of 2026-04-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Revenue from Contract with Customer
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-10
- 2026-04-30: Contract with Customer, Liability, Revenue Recognized $2.30M.
| Period end | Contract with Customer, Liability, Revenue Recognized |
|---|---|
| 2026-04-30 | $2.30M 10-Q · filed 2026-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |